# Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

> **NCT04239625** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Alkeus Pharmaceuticals, Inc.** · enrollment: 200 (estimated)

## Conditions studied

- Stargardt Disease
- Stargardt Macular Degeneration
- Stargardt Macular Dystrophy
- Autosomal Recessive Stargardt Disease 1 (ABCA4-related)

## Interventions

- **DRUG:** ALK-001

## Key facts

- **NCT ID:** NCT04239625
- **Lead sponsor:** Alkeus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-12-20
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04239625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04239625, "Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04239625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*